Hemophilia A

A phase 3 BASIS analysis examined the use of factor replacement therapy for breakthrough bleeds and the perioperative management of minor and dental procedures among patients receiving marstacimab...

A phase 3 trial evaluated weekly marstacimab prophylaxis in adolescents and adults with hemophilia A or B with inhibitors.

The FDA approval expands the use of marstacimab-hncq (Hympavzi; Pfizer Inc.) for routine prophylaxis to prevent or reduce bleeding episodes in additional pediatric and inhibitor-positive hemophilia A and B...